A Phase 2 interventional study of Sonelokimab (M1095) and Adalimumab in Hidradenitis Suppurativa, sponsored by MoonLake Immunotherapeutics AG. Completed at 57 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by MoonLake Immunotherapeutics AG · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Hidradenitis Suppurativa with a site in United States — 38 open to participants now, 55 under way, 12 of them phase 3. Hidradenitis Suppurativa · United States.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, this one is the 29th largest by enrollment of the 139 interventional ones that give a count, is one of 13 that started in 2022, is one of 61 in phase 2, and was the 87th registered.
285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
Browse Hidradenitis Suppurativa studies →38 of the 161 studies in Hidradenitis Suppurativa with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Novartis Pharmaceuticals · Sites in United States
Ages 18–65
Corvus Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Harrison Dermatology · Sites in United States
Ages 12+
Beth Israel Deaconess Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 65 · Phase 3 27 · Phase 4 5
First in 2005; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 45 across 200 interventional studies indexed under Hidradenitis Suppurativa.
Median enrollment 45 across the 139 interventional studies, 300 across the 22 observational. Of the 95 that completed or were terminated, 52 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 161 have an industry lead sponsor. The 10 most frequent:
MoonLake Immunotherapeutics AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
MoonLake Immunotherapeutics AG has 5 studies filed under Hidradenitis Suppurativa — fewer than ten, so there is no comparison to draw.
21 of the studies in Hidradenitis Suppurativa with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06468228Phase 3AbbVieA Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12 |
| NCT06921850Phase 3UCB Biopharma SRLA Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa | 2026-12-21 |
| NCT06212999Phase 3Incyte CorporationA Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa | 2026-12-26 |
| NCT06799000Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | 2027-05-17 |
| NCT06840392Phase 3Novartis PharmaceuticalsA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | 2027-06-03 |
Add all 21 to your calendar (.ics) → With an account.
Among the 161 studies in Hidradenitis Suppurativa with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
Drug: Sonelokimab (M1095)
Subjects randomized to this arm will receive assigned sonelokimab dosage regimen and placebo to maintain the blinding with adalimumab and placebo arms during the Treatment Period.
Drug: Sonelokimab (M1095)
Subjects randomized to this arm will receive placebo during the Double-Blind Treatment Period and will be re-randomized to receive a sonelokimab dosage regimen during Part B.
Other: Placebo
Subjects randomized to this arm will receive adalimumab during the Double-Blind Treatment Period and will be reallocated to receive sonelokimab dosage regimen during Part B.
Drug: Adalimumab
randomized treatment; parallel-group
randomized treatment; parallel-group
randomized treatment; parallel-group
Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12
HiSCR75 was defined as at least a 75% reduction from baseline in abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining fistula count. A non-responder imputation (NRI) method was used for missing data.
Time frame: At Week 12
Percentage of Participants Achieving HiSCR50 at Week 12
HiSCR50 was defined as at least a 50% reduction from baseline in abscess and AN count, with no increase from baseline in abscess or draining fistula count. An NRI method was used for missing data.
Time frame: At Week 12
Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 12
The IHS4 is a validated tool to dynamically assess hidradenitis suppurativa (HS) severity. The IHS4 score was calculated as: number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A total score of ≤3 signified mild, score of 4 to 10 signified moderate, and score of ≥11 signified severe disease. A negative change from baseline indicated an improvement in HS severity.
Time frame: Baseline and Week 12
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of ≤5 at Week 12
The DLQI is an instrument designed to assess the impact of the disease on a participant's dermatology-specific quality of life (QoL). The DLQI total score ranged from 0 to 30, with higher scores indicating greater health-related QoL impairment. A negative change from baseline indicated an improvement in health-related QoL. An NRI method was used for missing data.
Time frame: At Week 12
Percentage of Participants Achieving a Numerical Rating Scale (NRS) 30 in Patient's Global Assessment (PGA) of Skin Pain at Week 12, in Participants With Baseline NRS ≥3
The PGA of Skin Pain NRS in the past 24 hours was used to assess pain "at its worst" due to HS in the last 24 hours and was completed by the participant using the electronic Diary device. NRS scores ranged from 0 to 10, with higher scores indicating greater skin pain. The weekly averages score was calculated based on the available daily scores from the 7 days on or prior to the nominal day of the visit. The average of the 7 days on or before the date of first dose of trial treatment was used as baseline. A PGA skin pain responder was a participant who achieved NRS30, defined as at least 30% reduction and at least 1-unit reduction from baseline in NRS in PGA skin pain. An NRI method was used for missing data.
Time frame: At Week 12
Participants were enrolled in 7 countries in Europe and North America. The trial included a screening period of up to 4 weeks, a 12-week placebo-controlled treatment period (Part A), a 12-week active treatment period (Part B), and safety follow-up period of 4 weeks (with safety follow-up visit occurring 8 weeks \[± 7 days\] after the last dose of trial treatment).
| Milestone | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Part B: Placebo to Sonelokimab 120 mg | Part B: Placebo to Sonelokimab 240 mg | Part B: Sonelokimab 120 mg | Part B: Sonelokimab 240 mg | Part B: Adalimumab to Sonelokimab 240 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 68 | 67 | 66 | 33 | 0 | 0 | 0 | 0 | 0 |
| Completed | 64 | 66 | 64 | 32 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 4 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Part B: Placebo to Sonelokimab 120 mg | Part B: Placebo to Sonelokimab 240 mg | Part B: Sonelokimab 120 mg | Part B: Sonelokimab 240 mg | Part B: Adalimumab to Sonelokimab 240 mg |
|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 33 | 29 | 62 | 64 | 32 |
| Completed | 0 | 0 | 0 | 0 | 32 | 28 | 58 | 60 | 29 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 4 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
HiSCR75 was defined as at least a 75% reduction from baseline in abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining fistula count. A non-responder imputation (NRI) method was used for missing data.
| percentage of participants | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab |
|---|---|---|---|---|
| Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 75 at Week 12 | 14.7 | 43.3 | 34.8 | 36.4 |
HiSCR50 was defined as at least a 50% reduction from baseline in abscess and AN count, with no increase from baseline in abscess or draining fistula count. An NRI method was used for missing data.
| percentage of participants | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab |
|---|---|---|---|---|
| Percentage of Participants Achieving HiSCR50 at Week 12 | 27.9 | 65.7 | 53.0 | 57.6 |
The IHS4 is a validated tool to dynamically assess hidradenitis suppurativa (HS) severity. The IHS4 score was calculated as: number of nodules (multiplied by 1) plus the number of abscesses (multiplied by 2) plus the number of draining tunnels (multiplied by 4). A total score of ≤3 signified mild, score of 4 to 10 signified moderate, and score of ≥11 signified severe disease. A negative change from baseline indicated an improvement in HS severity.
| score on a scale | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab |
|---|---|---|---|---|
| Change From Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4) at Week 12 | -7.91 ± 2.11 | -19.32 ± 2.10 | -14.55 ± 2.10 | -15.46 ± 2.97 |
The DLQI is an instrument designed to assess the impact of the disease on a participant's dermatology-specific quality of life (QoL). The DLQI total score ranged from 0 to 30, with higher scores indicating greater health-related QoL impairment. A negative change from baseline indicated an improvement in health-related QoL. An NRI method was used for missing data.
| percentage of participants | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab |
|---|---|---|---|---|
| Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of ≤5 at Week 12 | 21.6 | 26.8 | 33.9 | 28.0 |
The PGA of Skin Pain NRS in the past 24 hours was used to assess pain "at its worst" due to HS in the last 24 hours and was completed by the participant using the electronic Diary device. NRS scores ranged from 0 to 10, with higher scores indicating greater skin pain. The weekly averages score was calculated based on the available daily scores from the 7 days on or prior to the nominal day of the visit. The average of the 7 days on or before the date of first dose of trial treatment was used as baseline. A PGA skin pain responder was a participant who achieved NRS30, defined as at least 30% reduction and at least 1-unit reduction from baseline in NRS in PGA skin pain. An NRI method was used for missing data.
| percentage of participants | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab |
|---|---|---|---|---|
| Percentage of Participants Achieving a Numerical Rating Scale (NRS) 30 in Patient's Global Assessment (PGA) of Skin Pain at Week 12, in Participants With Baseline NRS ≥3 | 17.0 | 40.0 | 54.3 | 57.1 |
Collected over Part A adverse event (AE) reporting: from first dose in Part A until end of Part A (for participants continuing to Part B), or completion of safety follow-up (for participants not continuing to Part B); up to maximum of 19 weeks. Part B AE reporting: from first dose in Part B until completion of safety follow-up; up to maximum of 17 weeks. All-cause mortality: from enrollment until completion of safety follow-up; up to maximum of 23 weeks in Part A or 21 weeks in Part B.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | 0/68 (0%) | 2/68 (2.9%) | 29/68 (42.6%) |
| Part A: Sonelokimab 120 mg | 0/67 (0%) | 2/67 (3%) | 39/67 (58.2%) |
| Part A: Sonelokimab 240 mg | 0/66 (0%) | 1/66 (1.5%) | 36/66 (54.5%) |
| Part A: Adalimumab | 0/33 (0%) | 0/33 (0%) | 21/33 (63.6%) |
| Part B: Placebo to Sonelokimab 120 mg | 0/33 (0%) | 0/33 (0%) | 14/33 (42.4%) |
| Part B: Placebo to Sonelokimab 240 mg | 0/29 (0%) | 0/29 (0%) | 17/29 (58.6%) |
| Part B: Sonelokimab 120 mg | 0/62 (0%) | 0/62 (0%) | 23/62 (37.1%) |
| Part B: Sonelokimab 240 mg | 0/64 (0%) | 0/64 (0%) | 30/64 (46.9%) |
| Part B: Adalimumab to Sonelokimab 240 mg | 0/32 (0%) | 1/32 (3.1%) | 12/32 (37.5%) |
| Event | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Part B: Placebo to Sonelokimab 120 mg | Part B: Placebo to Sonelokimab 240 mg | Part B: Sonelokimab 120 mg | Part B: Sonelokimab 240 mg | Part B: Adalimumab to Sonelokimab 240 mg |
|---|---|---|---|---|---|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/68 | 0/67 | 0/66 | 0/33 | 0/33 | 0/29 | 0/62 | 0/64 | 1/32 |
| Anorectal varices haemorrhageGastrointestinal disorders | 0/68 | 0/67 | 1/66 | 0/33 | 0/33 | 0/29 | 0/62 | 0/64 | 0/32 |
| Cerebrovascular accidentNervous system disorders | 0/68 | 1/67 | 0/66 | 0/33 | 0/33 | 0/29 | 0/62 | 0/64 | 0/32 |
| Genital painReproductive system and breast disorders | 0/68 | 1/67 | 0/66 | 0/33 | 0/33 | 0/29 | 0/62 | 0/64 | 0/32 |
| Cardiac failure chronicCardiac disorders | 1/68 | 0/67 | 0/66 | 0/33 | 0/33 | 0/29 | 0/62 | 0/64 | 0/32 |
| Proteus infectionInfections and infestations | 1/68 | 0/67 | 0/66 | 0/33 | 0/33 | 0/29 | 0/62 | 0/64 | 0/32 |
| Event | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Part B: Placebo to Sonelokimab 120 mg | Part B: Placebo to Sonelokimab 240 mg | Part B: Sonelokimab 120 mg | Part B: Sonelokimab 240 mg | Part B: Adalimumab to Sonelokimab 240 mg |
|---|---|---|---|---|---|---|---|---|---|
| Oral candidiasisInfections and infestations | 0/68 | 4/67 | 8/66 | 0/33 | 4/33 | 6/29 | 4/62 | 8/64 | 2/32 |
| NasopharyngitisInfections and infestations | 10/68 | 10/67 | 6/66 | 2/33 | 3/33 | 5/29 | 8/62 | 8/64 | 2/32 |
| HeadacheNervous system disorders | 8/68 | 6/67 | 8/66 | 3/33 | 2/33 | 5/29 | 3/62 | 1/64 | 1/32 |
| Upper respiratory tract infectionInfections and infestations | 3/68 | 4/67 | 7/66 | 4/33 | 1/33 | 2/29 | 3/62 | 7/64 | 2/32 |
| Injection site reactionGeneral disorders | 0/68 | 6/67 | 6/66 | 0/33 | 1/33 | 3/29 | 1/62 | 5/64 | 1/32 |
| Blood creatine phosphokinase increasedInvestigations | 1/68 | 2/67 | 4/66 | 3/33 | 0/33 | 0/29 | 0/62 | 1/64 | 0/32 |
| COVID-19Infections and infestations | 6/68 | 4/67 | 5/66 | 2/33 | 0/33 | 1/29 | 0/62 | 1/64 | 2/32 |
| HidradenitisSkin and subcutaneous tissue disorders | 0/68 | 2/67 | 1/66 | 1/33 | 2/33 | 2/29 | 1/62 | 1/64 | 1/32 |
| EczemaSkin and subcutaneous tissue disorders | 1/68 | 3/67 | 0/66 | 1/33 | 0/33 | 2/29 | 1/62 | 1/64 | 1/32 |
| Back painMusculoskeletal and connective tissue disorders | 1/68 | 0/67 | 0/66 | 0/33 | 0/33 | 2/29 | 4/62 | 1/64 | 1/32 |
The Full Analysis Set (FAS) included all randomized participants assigned treatment for Part A.
| Age, Continuous(years) | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Total |
|---|---|---|---|---|---|
| Mean | 39.3 ± 13.05 | 37.6 ± 10.46 | 36.2 ± 11.65 | 37.1 ± 10.55 | 37.6 ± 11.60 |
| Sex: Female, Male(Participants) | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Total |
|---|---|---|---|---|---|
| Female | 36 | 42 | 42 | 20 | 140 |
| Male | 32 | 25 | 24 | 13 | 94 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 2 | 5 | 2 | 12 |
| Not Hispanic or Latino | 62 | 63 | 58 | 31 | 214 |
| Unknown or Not Reported | 3 | 2 | 3 | 0 | 8 |
| Race/Ethnicity, Customized(Participants) | Part A: Placebo | Part A: Sonelokimab 120 mg | Part A: Sonelokimab 240 mg | Part A: Adalimumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 1 | 3 |
| Asian | 2 | 1 | 3 | 0 | 6 |
| Black or African American | 3 | 6 | 5 | 2 | 16 |
| White | 59 | 57 | 54 | 29 | 199 |
| Not reported | 4 | 2 | 3 | 1 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2022 to primary completion in May 2023, 12 months.
Results were first posted in Sep 2026, 3 years 4 months after primary completion. A results delay was requested in May 2024.
Of 44 industry-sponsored phase 2 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 12 months is below that.
Counting every sponsor, half of 54 studies reached it within 15 months; a quarter within 11 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonelokimab
MoonLake Immunotherapeutics AG